Sanjeev Deva
Overview
Explore the profile of Sanjeev Deva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roth S, Wilson K, Ramsay R, Mitchell C, Sampurno S, Pham T, et al.
Heliyon
. 2025 Jan;
11(1):e41364.
PMID: 39811281
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted...
2.
Verlingue L, Italiano A, Prenen H, Alia E, Tosi D, Perets R, et al.
EBioMedicine
. 2024 Oct;
109:105374.
PMID: 39395231
Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in...
3.
Robb T, Liu Y, Woodhouse B, Windahl C, Hurley D, McArthur G, et al.
NPJ Digit Med
. 2024 Sep;
7(1):261.
PMID: 39343807
We introduce a proof-of-concept extended reality (XR) environment for discussing cancer, presenting genomic information from multiple tumour sites in the context of 3D tumour models generated from CT scans. This...
4.
Prenen H, Deva S, Keam B, Lindsay C, Lugowska I, Yang J, et al.
Clin Cancer Res
. 2024 May;
30(14):2945-2953.
PMID: 38709220
Purpose: In this study, we report the results from the esophageal squamous cell carcinoma (SCC) cohort of a phase II, noncomparative, basket study evaluating the antitumor activity and safety of...
5.
Odegard J, Othman A, Lin K, Wang A, Nazareno J, Yoon O, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604815
Background: Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway...
6.
Tran K, Kolekar S, Wang Q, Shih J, Buchanan C, Deva S, et al.
Mol Cancer Ther
. 2022 Oct;
21(12):1777-1787.
PMID: 36198029
The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context....
7.
Hitchen N, Waldron N, Deva S, Findlay M, Lawrence B
Asia Pac J Clin Oncol
. 2022 Sep;
19(5):e231-e238.
PMID: 36114593
Background: First-line palliative chemotherapy regimens in advanced pancreatic adenocarcinoma include triplet chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan, and the doublet of nab-paclitaxel plus gemcitabine. Use of triplet chemotherapy in real-world...
8.
Lu Z, Yang S, Luo X, Shi Y, Lee J, Deva S, et al.
Gastric Cancer
. 2022 Jul;
25(5):943-955.
PMID: 35778636
Background: In solid tumor Phase 1/2 trials (NCT02407990; NCT04068519), tislelizumab demonstrated clinical benefit, including in advanced gastroesophageal adenocarcinoma (GEA). However, the majority of patients with GEA did not respond, highlighting...
9.
He J, Jackson C, Deva S, Hung T, Clarke K, Segelov E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Apr;
11(7):867-879.
PMID: 35470967
Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P-glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers...
10.
Cohen E, Nabell L, Wong D, Day T, Daniels G, Milhem M, et al.
Clin Cancer Res
. 2021 Dec;
28(6):1157-1166.
PMID: 34965944
Purpose: To determine whether SD-101, a Toll-like receptor 9 agonist, potentiates the antitumor activity of anti-PD-1 antibodies in patients with anti-PD-1/PD-L1 naïve, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)....